Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2009

View Archived Issues

Novel Janus kinase 2 inhibitors disclosed by Merck & Co.

AstraZeneca claims novel phthalazinone derivatives for cancer treatment

GSK reports novel glycine transporter inhibitors for schizophrenia treatment

Muscarinic M3 antagonists described by Pfizer for the treatment of COPD and asthma

Bayer claims novel compounds for the treatment of dyslipidemia

Biomarker identified for response to tipifarnib-bortezomib in acute myeloid leukemia

Saracatinib monotherapy shows little efficacy in advanced, castration-resistant prostate cancer

Novimmune designs antibodies with multiple specificities

Johnson & Johnson reviews first quarter 2009

Dainippon discontinues development of AC-3933 for dementia

Gilead begins phase II trial for integrase-based, single-tablet, once-daily HIV treatment

VentiRx initiates phase I VTX-1463 trial in allergic rhinitis

Galapagos and Merck to develop small-molecule drugs in inflammatory diseases

Preliminary results from ongoing phase I MDX-1401 trial in Hodgkin lymphoma patients reported

Multivalent, virosome-based breast cancer vaccine deemed safe, well tolerated in phase I trial

Pregabalin may be beneficial in patients with chronic hepatitis C

Advaxis initiates drug-licensing discussions in non-U.S. markets for ADXS11-001

PAION initiates phase Ib study of CNS-7056 in volunteers undergoing colonoscopy

Pharmacyclics and Servier enter global strategic alliance for PCI-24781

Adeona to acquire Colwell Clinical Laboratories

Amarillo supplies oral interferon for Australian human influenza study

Osiris completes enrollment in phase III Prochymal trial for graft vs. host disease

The European Commission withdraws marketing authorization for Velosulin

Gilead acquires CV Therapeutics

Factor VIIa inhibitors presented by Eisai for the treatment of thrombotic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...